{"groups":[{"description":"This is a phase II single-arm open-label study that will define responses to therapy with weekly intrathecal 131I-3F8 in patients with central nervous system/leptomeningeal GD2-expressing disease.\n\nDNA analysis\n\nimmunologic technique\n\npharmacological study\n\niodine I 131 monoclonal antibody 3F8\n\n131I-3F8: Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.","id":"FG000","title":"131I-3F8"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Enrolled but not treated"},{"reasons":[{"groupId":"FG000","numSubjects":"29"}],"type":"Removed due to progressive disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"78"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"45"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}